IP Library Granted Patent US 7,244,448
Granted Patent B2
US 7,244,448 · App. 09/896,812 · Granted Jul 17, 2007

Liposomal antineoplastic drugs and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,244,448
App. No.
09/896,812
Granted
Jul 17, 2007
Kind
B2
Abstract

This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.

Claims (5)

1. A liposomal formulation, said liposomal formulation comprising a liposome having vinorelbine in solution and precipitated vinorelbine, wherein the precipitated vinorelbine in said liposome is at least 50% of the total vinorelbine, wherein said liposome comprises sphingomyelin and cholesterol at a ratio in the range of about 75/25 mol %/mol % sphingomyelinl/cholesterol to about 30/50 mol %/mol % sphingomyelinl/cholesterol, and wherein the ratio of said vinorelbine to lipid is 0.2-0.3:1 (w/w).

2. The liposomal formulation of claim 1 , wherein said liposome comprises sphingomyelin and cholesterol in a 55:45 molar ratio.

3. The liposomal formulation of claim 1 , wherein said liposome comprises sphingomyelin and cholesterol in a 50:50 molar ratio.

4. The liposomal formulation of claim 1 , wherein the ratio of said vinorelbine to said lipid is about 0.3:1 (w/w).

5. A liposomal formulation, said liposomal formulation comprising a liposome having vinorelbine in solution and precipitated vinorelbine, wherein the precipitated vinorelbine in said liposome is at least 50% of the total vinorelbine, wherein said liposome comprises sphingomyelin and cholesterol at a ratio of about 55/45 mol %/mol % sphingomyelin/cholesterol, and wherein the ratio of said vinorelbine to lipid is about 0.3:1 (w/w).

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 16, 2023
From: SILICON VALLEY BANK
To: TEKMIRA PHARMACEUTICALS CORPORATION
Reel/Frame 062720/0919 →
RELEASE OF SECURITY INTEREST Recorded Jan 17, 2014
From: BANK OF MERICA, N.A.
To: SPECTRUM PHARMACEUTICALS, INC.
Reel/Frame 031996/0565 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 23, 2013
From: TALON THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 031263/0934 →